-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Downgrades Zenas BioPharma to Equal-Weight, Lowers Price Target to $19

Benzinga·01/06/2026 15:44:30
Listen to the news
Morgan Stanley analyst Judah Frommer downgrades Zenas BioPharma (NASDAQ:ZBIO) from Overweight to Equal-Weight and lowers the price target from $37 to $19.